DICE Therapeutics DICE Stock
DICE Therapeutics Price Chart
DICE Therapeutics DICE Financial and Trading Overview
| DICE Therapeutics stock price | 47.55 USD |
| Previous Close | 34.35 USD |
| Open | 34.3 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 33.6 - 35.04 USD |
| 52 Week Range | 13.34 - 45.99 USD |
| Volume | 355.77K USD |
| Avg. Volume | 475.15K USD |
| Market Cap | 1.65B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 61.3 USD |
DICE Valuation Measures
| Enterprise Value | 1.1B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.117302 |
| PEG Ratio (5 yr expected) | 0.69 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.010734 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -10.977 |
Trading Information
DICE Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 141.93% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 45.99 USD |
| 52 Week Low | 13.34 USD |
| 50-Day Moving Average | 32.72 USD |
| 200-Day Moving Average | 30.08 USD |
DICE Share Statistics
| Avg. Volume (3 month) | 475.15K USD |
| Avg. Daily Volume (10-Days) | 414.31K USD |
| Shares Outstanding | 47.73M |
| Float | 28.48M |
| Short Ratio | 17.43 |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 104.26% |
| Shares Short | 7.82M |
| Short % of Float | 26.22% |
| Short % of Shares Outstanding | 16.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.016% |
| Return on Equity (ttm) | -21.59% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -56075000 USD |
| EBITDA | -100020000 USD |
| Net Income Avi to Common (ttm) | -90942000 USD |
| Diluted EPS (ttm) | -2.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 554.55M USD |
| Total Cash Per Share (mrq) | 11.62 USD |
| Total Debt (mrq) | 12.94M USD |
| Total Debt/Equity (mrq) | 2.37 USD |
| Current Ratio (mrq) | 32.443 |
| Book Value Per Share (mrq) | 11.459 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -72594000 USD |
| Levered Free Cash Flow (ttm) | -44697124 USD |
Profile of DICE Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 400 East Jamie Court |
| ZIP | 94080 |
| Phone | 650 566 1402 |
| Website | https://www.dicetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 81 |
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Q&A For DICE Therapeutics Stock
What is a current DICE stock price?
DICE Therapeutics DICE stock price today per share is 47.55 USD.
How to purchase DICE Therapeutics stock?
You can buy DICE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for DICE Therapeutics?
The stock symbol or ticker of DICE Therapeutics is DICE.
Which industry does the DICE Therapeutics company belong to?
The DICE Therapeutics industry is Biotechnology.
How many shares does DICE Therapeutics have in circulation?
The max supply of DICE Therapeutics shares is 47.76M.
What is DICE Therapeutics Price to Earnings Ratio (PE Ratio)?
DICE Therapeutics PE Ratio is 0.00000000 now.
What was DICE Therapeutics earnings per share over the trailing 12 months (TTM)?
DICE Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the DICE Therapeutics company belong to?
The DICE Therapeutics sector is Healthcare.
DICE Therapeutics DICE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2060.1 USD — |
-1.99
|
— — | 2051.95 USD — | 2093.4 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2541.54 USD — |
-1.89
|
— — | 2531.95 USD — | 2572.66 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}